DiA Secures FDA Clearance and CE Mark for Additional AI-Based Ultrasound Analysis Solutions for Use on the COVID-19 Frontlines

Share Article

DiA’s new AI-based LVivo RV enables rapid assessment of right ventricle dysfunction in COVID-19 patients, while LVivo Bladder supports clinicians with automated bladder volume analysis to minimize scan time and risk of infection

DiA’s LVivo RV uses AI to immediately detect signs of right ventricle dysfunction

DiA Imaging Analysis, a leading provider of advanced AI-based solutions for ultrasound analysis, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) 510(k) and a European CE mark for two additional AI-powered ultrasound analysis solutions.

  • LVivo RV is the first AI-based fully automated analysis of the heart’s right ventricle (RV) and can be used to diagnose and monitor right heart ailments in acute and chronic patients suspected to have RV injury, including those with COVID-19.
  • LVivo Bladder uses AI to deliver automated bladder volume measurements on ultrasound devices, significantly reducing patient scanning time and risk of infection.

Both solutions join DiA’s LVivo Toolbox, of now six FDA/CE-cleared AI-powered ultrasound solutions in total. The company was recently awarded a COVID-19-specific government grant from Israel’s Innovation Authority to accelerate access to its AI-based offerings in response to the COVID-19 pandemic.

“Physicians now face a host of new challenges and restrictions on the frontlines that underscores the critical role of ultrasound and value of having access to AI-powered solutions,” said Hila Goldman-Aslan, DiA’s CEO and Co-Founder. “With today’s FDA and CE approvals, DiA takes a big step toward strengthening our AI offerings for cardiac ultrasound while realizing our vision of making ultrasound analysis smarter and more accessible across a broader range of healthcare segments.”

There is growing evidence linking COVID-19 mortality and right ventricle heart failure. A study at Mount Sinai Morningside Hospital found that 31% of the patients hospitalized with COVID-19 had right ventricle failure, and that 41% of patients in this subset who died had signs of RV dilation or enlargement. By automatically providing quantified 2D analysis of the RV’s size and function, LVivo RV helps detect and monitor right heart failure. LVivo RV utilizes DiA’s flagship LVivo Artificial Intelligence platform to deliver faster, more accurate analysis while at the same time enabling clinicians to shorten patient scanning and evaluation time.

“The RV has always been very difficult to evaluate, due to its unique structure and location,” said Dr. Anthony M. Demaria, a leading cardiologist at University of California, San Diego (UCSD) Medical Center and a co-investigator of the multi-center study for LVivo RV. “This is further compounded by the complexity of the analysis itself, which relies on a combination of manual calculations and visual user input. LVivo RV is a welcome and very useful addition to clinicians’ toolbox for more quickly and effectively monitoring the right ventricle.”

Additional co-investigators of the study included Dr. David Rosenmann and Dr. Shemi Carasso at Israel’s Shaare Zedek Medical Center and Baruch Padeh Medical Center, respectively.

With LVivo Bladder, DiA extends its expertise beyond cardiology to abdominal ultrasound. Healthcare-associated urinary tract infections (UTIs) account for up to 40% of infections in hospitals and 23% of infections in the intensive care unit (ICU). LVivo Bladder enables ultrasound users to automatically and accurately measure bladder volume, which is currently done on cart-based systems manually or by dedicated bladder scanners. LVivo Bladder’s automated volume calculation turns any ultrasound device into a bladder scanner, minimizing patient scanning time and helping to prevent unnecessary catheterization to reduce the risk of infection.

About DiA Imaging Analysis:
DiA Imaging Analysis is a leading provider of AI-powered ultrasound analysis solutions that transform the way clinicians use and analyze ultrasound images. DiA was named one of eight companies to watch for AI imaging technology by DAIC Magazine and is leading the way in FDA/CE-cleared AI products for ultrasound. Its vendor neutral LVivo AI solutions use a combination of image processing, machine learning and deep neural network algorithms to automatically detect clinical parameters and abnormalities in ultrasound images. LVivo solutions allow clinicians with various levels of ultrasound experience to use and analyze ultrasound images on their ultrasound devices or healthcare IT system with increased speed, efficiency and accuracy. DiA currently serves thousands of end-users worldwide.

For additional information, please visit http://www.dia-analysis.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Kuller
Visit website